Form 4: GeneDx Holdings Corp. CFO Kevin Feeley Reports Stock Transactions

Kevin Feeley, CFO of GeneDx Holdings Corp., reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Summary

• On April 29, 2025, Kevin Feeley, CFO of GeneDx Holdings Corp., acquired 753 Class A Common Stock shares through the vesting of Restricted Stock Units (RSUs) at $0 cost.
• Feeley also sold 388 Class A Common Stock shares at $113.09 to cover tax withholding obligations related to the RSU vesting.
• On April 30, 2025, Feeley acquired 420 shares of Class A Common Stock at $56.8225 under the Employee Stock Purchase Plan.
• Following these transactions, Feeley directly owns 3,757 shares of Class A Common Stock and 3,014 Restricted Stock Units.
• The RSUs vest over time, with 25% vesting on April 29, 2023, and April 29, 2024, and the remainder vesting quarterly until April 29, 2026, contingent upon continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and expected, with no indication of significant positive or negative sentiment from the insider's actions. The sale of shares to cover taxes is a common practice.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates confidence in the company's future.

Negatives

• The sale of shares to cover tax obligations, while routine, could be perceived negatively if investors are highly sensitive to insider selling.

Risks

• Continued vesting of RSUs could lead to further sales to cover tax obligations, potentially creating downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs extends until April 29, 2026.

Industry Context

Form 4 filings are standard practice and provide transparency into insider transactions, allowing investors to monitor management's actions and sentiment regarding the company's stock.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the reported transactions appear to be routine, such as vesting of RSUs and participation in employee stock purchase plans.
• Comparable companies in the biotech or healthcare sector also regularly disclose similar insider transactions through Form 4 filings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for slight price fluctuations from the sale of shares to cover tax obligations.
• Employees participating in the Employee Stock Purchase Plan benefit from the opportunity to acquire company stock at potentially favorable prices.

Key Dates

Keywords

GeneDx Holdings Corp., Kevin Feeley, CFO, Class A Common Stock, Restricted Stock Units, RSU, Employee Stock Purchase Plan, Insider Trading, Form 4, Vesting